Cargando…

Cancer immunity marker RNA expression levels across gynecologic cancers: Implications for immunotherapy

BACKGROUND: Our objective was to characterize cancer immunity marker expression in gynecologic cancers and compare immune landscapes between gynecologic tumor subtypes and with non-gynecologic solid tumors. METHODS: RNA expression levels of 51 cancer-immunity markers were analyzed in patients with g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jou, Jessica, Kato, Shumei, Miyashita, Hirotaka, Thangathurai, Kartheeswaran, Pabla, Sarabjot, DePietro, Paul, Nesline, Mary, Conroy, Jeffrey, Rubin, Eitan, Eskander, Ramez, Kurzrock, Razelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Journal Experts 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949233/ https://www.ncbi.nlm.nih.gov/pubmed/36824739 http://dx.doi.org/10.21203/rs.3.rs-2551645/v1

Ejemplares similares

T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy
por: Miyashita, Hirotaka, et al.
Publicado: (2023)

LAG‐3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics
por: Adashek, Jacob J., et al.
Publicado: (2023)

Immune profiling and immunotherapeutic targets in pancreatic cancer
por: Lenzo, Felicia L., et al.
Publicado: (2021)

Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients
por: Charo, Lindsey M., et al.
Publicado: (2020)

Chromatin remodeling (SWI/SNF) complexes, cancer, and response to immunotherapy
por: Krishnamurthy, Nithya, et al.
Publicado: (2022)

Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy
por: Louie, Bryan H., et al.
Publicado: (2022)

PD-L1 Expression by RNA-Sequencing in Non-Small Cell Lung Cancer: Concordance with Immunohistochemistry and Associations with Pembrolizumab Treatment Outcomes
por: Nesline, Mary K., et al.
Publicado: (2023)

Integration of tumor inflammation, cell proliferation, and traditional biomarkers improves prediction of immunotherapy resistance and response
por: Pabla, Sarabjot, et al.
Publicado: (2021)

KRAS‐Mutated, Estrogen Receptor‐Positive Low‐Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery
por: Kato, Shumei, et al.
Publicado: (2021)

SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer
por: Botta, Gregory P., et al.
Publicado: (2021)

Promoting Precision Cancer Medicine through a Community-Driven Knowledgebase
por: Geifman, Nophar, et al.
Publicado: (2014)

Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach
por: Kato, Shumei, et al.
Publicado: (2017)

Immunotherapy in endometrial cancer - an evolving therapeutic paradigm
por: Longoria, Teresa C., et al.
Publicado: (2015)

The paradox of cancer genes in non-malignant conditions: implications for precision medicine
por: Adashek, Jacob J., et al.
Publicado: (2020)

Erratum to: Immunotherapy in endometrial cancer - an evolving therapeutic paradigm
por: Longoria, Teresa C., et al.
Publicado: (2016)

Liquid biopsy: current technology and clinical applications
por: Nikanjam, Mina, et al.
Publicado: (2022)

Of Mice, Not Men: When the Bench-to-Bedside Bridge Is Broken
por: Nikanjam, Mina, et al.
Publicado: (2022)

Unique Genomic Landscape of High-Grade Neuroendocrine Cervical Carcinoma: Implications for Rethinking Current Treatment Paradigms
por: Eskander, Ramez N., et al.
Publicado: (2020)

Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease
por: Cohen, Philip R., et al.
Publicado: (2017)

A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors
por: Conroy, Jeffrey M., et al.
Publicado: (2021)

Immunotherapy as a treatment strategy in advanced stage and recurrent endometrial cancer: review of current phase III immunotherapy clinical trials
por: Eskander, Ramez N., et al.
Publicado: (2021)

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
por: Okamura, Ryosuke, et al.
Publicado: (2020)

Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer
por: Eskander, Ramez N, et al.
Publicado: (2013)

Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric/GEJ Cancer
por: Adashek, Jacob J., et al.
Publicado: (2020)

Unravelling the underpinnings of hyperprogression and immunotherapy: back to the bench
por: Subbiah, Vivek, et al.
Publicado: (2022)

Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity
por: Kato, Shumei, et al.
Publicado: (2020)

Can surgical management of bone metastases improve quality of life among women with gynecologic cancer?
por: Ji, Tao, et al.
Publicado: (2014)

The Conundrum of Genetic “Drivers” in Benign Conditions
por: Kato, Shumei, et al.
Publicado: (2016)

The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match
por: Subbiah, Vivek, et al.
Publicado: (2018)

Immunotherapy in gynecological cancers
por: Lorusso, Domenica, et al.
Publicado: (2021)

Concordance between cancer gene alterations in tumor and circulating tumor DNA correlates with poor survival in a real‐world precision‐medicine population
por: Rosenberg, Shai, et al.
Publicado: (2023)

Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse Malignancies
por: Shayeb, Akram Mesleh, et al.
Publicado: (2023)

ALK fusions in the pan-cancer setting: another tumor-agnostic target?
por: Shreenivas, Aditya, et al.
Publicado: (2023)

Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy
por: Magbanua, Mark Jesus M., et al.
Publicado: (2022)

Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer
por: Patel, Hitendra, et al.
Publicado: (2019)

Development and analytical validation of a next-generation sequencing based microsatellite instability (MSI) assay
por: Pabla, Sarabjot, et al.
Publicado: (2019)

Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy
por: Cohen, Philip R, et al.
Publicado: (2020)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab
por: George, Saby, et al.
Publicado: (2018)

MHC-I genotype and tumor mutational burden predict response to immunotherapy
por: Goodman, Aaron M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_13vek4t0q7p5urrua84k8rv0ta